BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-57@pharmaconomics
DTSTAMP:20260707T021627Z
DTSTART;VALUE=DATE:20270218
DTEND;VALUE=DATE:20270219
SUMMARY:AZN Phase 3 — Zibotentan/Dapagliflozin
DESCRIPTION:Phase 3 trial results for Zibotentan/Dapagliflozin in Chronic Kidney Disease With High Proteinuria are due Feb 18\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT06087835\n\nTrack it: https://pharmaconomics.com/e/57
URL:https://pharmaconomics.com/e/57
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:AZN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR